Search for: "Bristol Myers Squibb Manufacturing Company"
Results 61 - 80
of 161
Sort by Relevance
|
Sort by Date
9 Nov 2015, 7:39 am
BackgroundOno owns a patent relating to immunotherapy -- specifically the use of anti-PD-1 antibodies for treating cancer (and Bristol-Myers Squibb is the exclusive licensee). [read post]
2 Nov 2015, 7:42 am
Its joint manufacturers, Pfizer and Bristol-Myers Squibb, have recently kicked off a targeted direct-to-consumer advertising campaign to market the drug for a-fib treatment as well as for newly approved uses. [read post]
15 Sep 2015, 8:40 am
One of the four drugs is Eliquis, manufactured by Bristol-Myers Squibb (BMS), and, according to recent article from Forbes, the drugmaker has a lot riding on Eliquis sales. [read post]
3 Sep 2015, 7:34 am
Eliquis, manufactured by Bristol-Myers Squibb (BMS) and Pfizer, is now claiming its new oral anticoagulant (NOAC) is safer than other NOACs (Xarelto, Pradaxa, and Savaysa), according to a recent news article from Medpage Today. [read post]
9 Jul 2015, 3:28 pm
Xarelto, has grabbed a 32 percent market share in the highly competitive anticoagulant market, significantly ahead of Boehringer’s Pradaxa and Bristol-Myers Squibb’s Eliquis, the other two new anticoagulants in the market. [read post]
26 Jun 2015, 11:30 am
Our readers already know that it took the California Supreme Court less than four months to depublish Bristol-Myers Squibb (reported here). [read post]
19 Jun 2015, 6:30 am
Food and Drug Administration (FDA) approved the first AB-rated generics to Bristol-Myers Squibb and Otsuka’s Abilify® (aripiprazole) tablets, an atypical antipsychotic drug commonly used for treating schizophrenia and bipolar disorder. [read post]
26 May 2015, 7:42 am
Bristol-Myers Squibb Co., 2011 WL 4708850 (D. [read post]
25 Apr 2015, 11:03 am
The first edition of the Reference Manual on Scientific Evidence [Manual] was published in 1994, a year after the Supreme Court delivered its opinion in Daubert. [read post]
24 Mar 2015, 11:54 am
Xarelto, has grabbed a 32 percent market share in the highly competitive anticoagulant market, significantly ahead of Boehringer’s Pradaxa and Bristol-Myers Squibb’s Eliquis, the other two new anticoagulants in the market. [read post]
26 Feb 2015, 5:00 am
In Henderson, the plaintiff failed to prove negligence but claimed that “‘even if the Drug Company was not negligent . [read post]
13 Feb 2015, 12:00 pm
At issue in the case were Bristol-Myers Squibb’s anticoagulant Coumadin and AstraZeneca’s ulcer drugs Prilosec and Nexium. [read post]
21 Jan 2015, 3:02 pm
Its corporate talking heads (Bristol-Myers Squibb and Pfizer) said such spending helps ensure that providers understand its appropriate use, and how important it is “to have a speaker program that adequately provides robust education to these physicians. [read post]
24 Dec 2014, 5:00 am
” Being liable for purported defects in a competing product means, of course, that the costs of such liability can only be recouped by charging ones own customers more for other, non-defective products, but there are more plaintiff lawyers than innovator drug companies in Alabama. [read post]
8 Aug 2014, 5:00 am
In Bristol-Myers Squibb Co. v. [read post]
18 Jul 2014, 11:55 am
We are unwilling to make brand manufacturers the de facto insurers for competing generic manufacturers. [read post]
19 Jun 2014, 8:11 am
TAP Pharmaceuticals (Bristol Myers Squibb Appeal), No. 85 MAP 2011, slip op. [read post]
16 Jun 2014, 4:45 am
See Bristol-Myers Squibb Co. v. [read post]
12 Jun 2014, 10:41 am
Bristol-Myers Squibb Company v. [read post]
15 May 2014, 11:40 am
I accept that, for the reasons explained by Jacob J in Bristol-Myers Squibb and Lord Hoffmann in Kirin-Amgen, courts should be cautious before relying upon prosecution history as an aid to construction. [read post]
